投资工具 / 美股
Johnson & Johnson · JNJ
数据仅供参考,不构成投资建议。
投资工具 / 美股
数据仅供参考,不构成投资建议。
| 季度 | 截止日 | 申报日 | 营收 | 营收同比 g | Δg | 推导方式 |
|---|---|---|---|---|---|---|
| 2026Q3 | 2026-09-27 | 2026-10-21 | $25.4B | +5.9% | −0.7pp | 3M |
| 2026Q2 | 2026-06-28 | 2026-07-23 | $25.31B | +6.6% | −3.3pp | 3M |
| 2026Q1 | 2026-03-29 | 2026-04-22 | $24.06B | +9.9% | +0.8pp | 3M |
| 2025Q4 | 2025-12-28 | 2026-10-21 | $24.56B | +9.1% | +2.3pp | FY-9M |
| 2025Q3 | 2025-09-28 | 2026-10-21 | $23.99B | +6.8% | +1.0pp | 3M |
| 2025Q2 | 2025-06-29 | 2026-07-23 | $23.74B | +5.8% | +3.4pp | 3M |
| 2025Q1 | 2025-03-30 | 2026-04-22 | $21.89B | +2.4% | −2.9pp | 3M |
| 2024Q4 | 2024-12-29 | 2026-02-11 | $22.52B | +5.3% | +0.0pp | FY-9M |
口径:单季同比;Δg = 本季 g − 上季 g;按财季映射日历季度;申报日可见。† 不连续点(上年同季营收 ≤0 或 Δg 幅度超过 50pp)。 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| 季度 | 截止日 | 毛利 | 销货成本 | 毛利率 | 环比 | 同比 | Δ² |
|---|---|---|---|---|---|---|---|
| 2026Q3 | 2026-09-27 | $17.3B | $8.1B | 68.1% | −7bp | −144bp | −176bp |
| 2026Q2 | 2026-06-28 | $17.26B | $8.05B | 68.2% | +188bp | +32bp | +40bp |
| 季度 | 截止日 | 合同负债 | CL g | RPO | RPO g | 账单额 | 账单额 g | RPO 覆盖 |
|---|---|---|---|---|---|---|---|---|
| 2026Q3 | 2026-09-27 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 |
| 2026Q2 | 2026-06-28 | 无数据 | 无数据 |
| 季度 | 截止日 | OCF TTM | OCF g | CapEx TTM | CapEx g | FCF TTM | CapEx 密度 | SBC/FCF | SBC/Rev |
|---|---|---|---|---|---|---|---|---|---|
| 2026Q3 | 2026-09-27 | $26.16B | +8.1% | $5.57B | +20.9% | $20.59B | 5.6% | 6.9% | 1.4% |
| 2026Q2 | 2026-06-28 | $27.61B |
| 季度 | 截止日 | 存货 | 存货 g | 营收 g | 剪刀差 | DIO | DIO 同比 |
|---|---|---|---|---|---|---|---|
| 2026Q3 | 2026-09-27 | $15.38B | +8.7% | +5.9% | +2.8pp | 173.3 | −3.5 |
| 2026Q2 | 2026-06-28 | $15.14B | +12.9% | +6.6% | +6.3pp | 171.6 |
| 交易日 | 申报日 | 申报人 | 头衔 | 代码 | 股数 | 价格 | 金额 | 10b5-1 |
|---|---|---|---|---|---|---|---|---|
| 2026-11-12 | 2026-11-13 | Forminard Elizabeth | EVP, Chief Legal Officer | S | 13,072 | $284.39 | $3.72M |
口径:修正广度 =(近 30 日上调 − 下调)/(上调 + 下调),样本 < 3 不出;只展示衍生指标,不展示一致预期原值。 · 数据截至 2026-11-16 · 来源:Yahoo Finance / Nasdaq
未覆盖(期权覆盖为 S&P 500 期权持仓前 100 名每日、其余每周轮换)
口径:本股的警报事件历史(含基线);事件保留 90 天。
| 2026Q1 | 2026-03-29 | $15.96B | $8.11B | 66.3% | −125bp | −8bp | +70bp |
| 2025Q4 | 2025-12-28 | $16.6B | $7.97B | 67.6% | −200bp | −79bp | −133bp |
| 2025Q3 | 2025-09-28 | $16.69B | $7.3B | 69.6% | +169bp | +55bp | +207bp |
| 2025Q2 | 2025-06-29 | $16.12B | $7.63B | 67.9% | +148bp | −153bp | +163bp |
| 2025Q1 | 2025-03-30 | $14.54B | $7.36B | 66.4% | −195bp | −315bp | −328bp |
| 2024Q4 | 2024-12-29 | $15.39B | $7.13B | 68.3% | −67bp | +12bp | +17bp |
口径:GM = 毛利/营收;毛利缺失时用 营收−销货成本 推导;环比/同比为基点。 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| 无数据 |
| 无数据 |
| 无数据 |
| 无数据 |
| 2026Q1 | 2026-03-29 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 |
| 2025Q4 | 2025-12-28 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 |
| 2025Q3 | 2025-09-28 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 |
| 2025Q2 | 2025-06-29 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 |
| 2025Q1 | 2025-03-30 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 |
| 2024Q4 | 2024-12-29 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 | 无数据 |
口径:g = 同比;账单额 = 营收 + Δ合同负债(同口径);RPO 覆盖 = RPO / TTM 营收。跨口径(总额/仅流动)不比较。 合同负债口径: — · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| +19.9% |
| $5.36B |
| +19.8% |
| $22.24B |
| 5.5% |
| 6.4% |
| 1.4% |
| 2026Q1 | 2026-03-29 | $22.87B | −7.7% | $5.09B | +15.3% | $17.78B | 5.3% | 7.7% | 1.4% |
| 2025Q4 | 2025-12-28 | $24.53B | +1.1% | $4.83B | +9.2% | $19.7B | 5.1% | 6.9% | 1.4% |
| 2025Q3 | 2025-09-28 | $24.2B | −3.7% | $4.61B | +4.7% | $19.6B | 5.0% | 6.5% | 1.4% |
| 2025Q2 | 2025-06-29 | $23.03B | −6.5% | $4.48B | +3.2% | $18.55B | 4.9% | 6.6% | 1.4% |
| 2025Q1 | 2025-03-30 | $24.78B | +6.9% | $4.41B | −1.7% | $20.37B | 4.9% | 5.7% | 1.3% |
| 2024Q4 | 2024-12-29 | $24.27B | +6.5% | $4.42B | −2.6% | $19.84B | 5.0% | 5.9% | 1.3% |
口径:TTM = 近四个离散单季之和;FCF = OCF − CapEx;CapEx 密度 = CapEx/营收 TTM;FCF≤0 时 SBC/FCF 不计算。 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| +11.2 |
| 2026Q1 | 2026-03-29 | $14.58B | +15.2% | +9.9% | +5.3pp | 164.2 | +7.2 |
| 2025Q4 | 2025-12-28 | $14.19B | +14.0% | +9.1% | +5.0pp | 162.5 | +3.2 |
| 2025Q3 | 2025-09-28 | $14.15B | +12.2% | +6.8% | +5.5pp | 176.8 | +11.6 |
| 2025Q2 | 2025-06-29 | $13.41B | +10.2% | +5.8% | +4.4pp | 160.4 | −1.2 |
| 2025Q1 | 2025-03-30 | $12.66B | +11.2% | +2.4% | +8.8pp | 157.0 | −2.5 |
| 2024Q4 | 2024-12-29 | $12.44B | +11.3% | +5.3% | +6.0pp | 159.3 | +9.2 |
口径:剪刀差 = 存货同比 − 营收同比(pp,正值=存货增速快于营收);DIO = 存货/销货成本 × 91.25 天。 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| 2026-09-02 | 2026-09-04 | Schmid Timothy | EVP, WW Chair, MedTech | S | 11,070 | $274.74 | $3.04M |
| 2026-09-02 | 2026-09-04 | Schmid Timothy | EVP, WW Chair, MedTech | S | 22,527 | $274.74 | $6.19M |
| 2026-08-17 | 2026-08-18 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | S | 15,000 | $263.36 | $3.95M |
| 2026-08-13 | 2026-08-14 | Duato Joaquin | CEO and Chairman of the Board | S | 102,315 | $261.00 | $26.7M |
| 2026-08-13 | 2026-08-14 | Duato Joaquin | CEO and Chairman of the Board | S | 20,976 | $262.00 | $5.5M |
| 2026-08-06 | 2026-08-07 | Forminard Elizabeth | EVP, Chief Legal Officer | S | 9,344 | $257.76 | $2.41M |
| 2026-08-06 | 2026-08-07 | Forminard Elizabeth | EVP, Chief Legal Officer | S | 6,574 | $255.93 | $1.68M |
| 2026-08-05 | 2026-08-07 | Duato Joaquin | CEO and Chairman of the Board | S | 6,523 | $258.74 | $1.69M |
| 2026-08-05 | 2026-08-07 | Duato Joaquin | CEO and Chairman of the Board | S | 41,957 | $258.06 | $10.83M |
| 2026-07-20 | 2026-07-21 | Broadhurst Vanessa | EVP, Global Corp Affairs | S | 23,054 | $251.27 | $5.79M |
| 2026-06-11 | 2026-06-12 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | S | 10,000 | $241.15 | $2.41M |
| 2026-02-27 | 2026-03-03 | Decker Robert J | VP Corporate Controller | S | 4,075 | $247.87 | $1.01M |
| 2026-02-20 | 2026-02-23 | Schmid Timothy | EVP, WW Chair, MedTech | S | 1,322 | $245.66 | $324.76K |
| 2026-02-18 | 2026-02-18 | Schmid Timothy | EVP, WW Chair, MedTech | S | 13,625 | $244.20 | $3.33M |
| 2026-02-18 | 2026-02-18 | Schmid Timothy | EVP, WW Chair, MedTech | S | 8,998 | $244.53 | $2.2M |
| 2026-02-17 | 2026-02-18 | Swanson James D. | EVP, CIO | S | 20,521 | $242.70 | $4.98M |
| 2026-02-17 | 2026-02-18 | Wolk Joseph J | Exec VP, CFO | S | 12,066 | $242.87 | $2.93M |
| 2026-02-17 | 2026-02-18 | Wolk Joseph J | Exec VP, CFO | S | 33,386 | $242.75 | $8.1M |
| 2026-02-17 | 2026-02-18 | Wolk Joseph J | Exec VP, CFO | S | 24,961 | $242.68 | $6.06M |
| 2026-02-17 | 2026-02-18 | Wolk Joseph J | Exec VP, CFO | S | 19,241 | $242.99 | $4.68M |
| 2026-02-17 | 2026-02-18 | REED JOHN C | EVP, Innovative Medicine, R&D | S | 21,721 | $243.00 | $5.28M |
| 2026-02-17 | 2026-02-18 | REED JOHN C | EVP, Innovative Medicine, R&D | S | 2,283 | $243.00 | $554.77K |
| 2026-02-17 | 2026-02-18 | REED JOHN C | EVP, Innovative Medicine, R&D | S | 29,927 | $243.00 | $7.27M |
| 2026-02-17 | 2026-02-18 | Broadhurst Vanessa | EVP, Global Corp Affairs | S | 6,197 | $243.39 | $1.51M |
| 2026-02-13 | 2026-02-18 | Swanson James D. | EVP, CIO | S | 22,191 | $243.71 | $5.41M |
| 2026-02-13 | 2026-02-18 | Swanson James D. | EVP, CIO | S | 19,368 | $243.76 | $4.72M |
| 2026-01-26 | 2026-01-28 | Duato Joaquin | CEO and Chairman of the Board | S | 51,218 | $220.99 | $11.32M |
| 2026-01-26 | 2026-01-28 | Duato Joaquin | CEO and Chairman of the Board | S | 48,782 | $221.48 | $10.8M |
| 2025-11-26 | 2025-12-01 | MORIKIS JOHN G | — | P | 1,250 | $206.15 | $257.69K |
| 2025-10-17 | 2025-10-20 | REED JOHN C | EVP, Innovative Medicine, R&D | S | 21,721 | $192.71 | $4.19M |
| 2025-09-04 | 2025-09-05 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | S | 56,471 | $177.81 | $10.04M |
| 2025-08-22 | 2025-08-25 | Duato Joaquin | CEO and Chairman of the Board | S | 125,824 | $179.21 | $22.55M |
| 2025-08-15 | 2025-08-18 | Wolk Joseph J | Exec VP, CFO | S | 16,820 | $176.91 | $2.98M |
| 2025-07-17 | 2025-07-18 | REED JOHN C | EVP, Innovative Medicine, R&D | S | 19,137 | $163.55 | $3.13M |
| 2025-02-25 | 2025-02-26 | Decker Robert J | VP Corporate Controller | S | 6,999 | $165.88 | $1.16M |
| 2025-02-18 | 2025-02-18 | Schmid Timothy | EVP, WW Chair, MedTech | S | 403 | $156.15 | $62.93K |
| 2025-02-07 | 2025-02-11 | Wolk Joseph J | Exec VP, CFO | S | 13,015 | $153.89 | $2M |
| 2024-12-12 | 2024-12-12 | WEINBERGER MARK A | — | P | 1,000 | $147.22 | $147.22K |
口径:Form 4/4A 公开市场买入(P)与卖出(S),申报人为董事或高管;汇总与集群为近 365 天,明细为最近 40 笔。 · 数据截至 2026-11-16 · 来源:SEC EDGAR Form 4
口径:SI 来自 FINRA(双周结算);SI% 分母 = SEC 封面总股本;借券费为 IBKR 报价(非全市场);卖空占比 = 当日卖空量/总成交量。 · 数据截至 SI 2026-10-30 · Reg SHO 2026-11-16 · 借券 2026-11-11 · 沿用上一版 · 来源:FINRA、IBKR、iBorrowDesk